Interaction of Alzheimer Amyloid Peptide with Cell Surfaces and Artificial Membranes

Lipids and Cellular Membranes in Amyloid Diseases

Volumn , Issue , 2011, Pages 231-243

  Bateman, David A ^a   Chakrabartty, Avijit ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

A peptide; Alzheimer's disease; Amyloid; Fluorescent confocal microscopy; Immunohistochemistry; Senile plaques

Indexed keywords

EID: 84874990538     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527634323.ch11     Document Type: Chapter

References (59)

1. Alzheimer, A. (1907) Uber eine eigenartige Erkankung der Hirnrinde. Allg. Z Psychiatr. Psych.-Gericht. Med., 64, 146-148.
2. Glenner, G.G. and Wong, C.W. (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun., 120, 885-890.
3. Huang, T.H., Yang, D.S., Plaskos, N.P., Go, S., Yip, C.M., Fraser, P.E., and Chakrabartty, A. (2000) Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide. J. Mol. Biol., 297, 73-87.
4. Nybo, M., Svehag, S.E., and Holm Nielsen, E. (1999) An ultrastructural study of amyloid intermediates in A beta1-42 fibrillogenesis. Scand. J. Immunol., 49, 219-223.
5. Blackley, H.K., Sanders, G.H., Davies, M.C., Roberts, C.J., Tendler, S.J., and Wilkinson, M.J. (2000) In-situ atomic force microscopy study of betaamyloid fibrillization. J. Mol. Biol., 298, 833-840.
6. Walsh, D.M., Lomakin, A., Benedek, G.B., Condron, M.M., and Teplow, D.B. (1997) Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem., 272, 22364-22372.
7. Harper, J.D., Wong, S.S., Lieber, C.M., and Lansbury, P.T. (1997) Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem. Biol., 4, 119-125.
8. Stine, W.B.J., Snyder, S.W., Ladror, U.S., Wade, W.S., Miller, M.F., Perun, T.J., Holzman, T.F., and Krafft, G.A. (1996) The nanometer-scale structure of amyloid-beta visualized by atomic force microscopy. J. Protein Chem., 15, 193-203.
9. Bitan, G., Lomakin, A., and Teplow, D.B. (2001) Amyloid beta-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J. Biol. Chem., 276, 35176-35184.
10. Gorman, P.M., Yip, C.M., Fraser, P.E., and Chakrabartty, A. (2003) Alternate aggregation pathways of the Alzheimer beta-amyloid peptide: Abeta association kinetics at endosomal pH. J. Mol. Biol., 325, 743-757.
11. Lambert, M.P., Barlow, A.K., Chromy, B.A., Edwards, C., Freed, R., Liosatos, M., Morgan, T.E., Rozovsky, I., Trommer, B., Viola, K.L., Wals, P., Zhang, C., Finch, C.E., Krafft, G.A., and Klein, W.L. (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA, 95, 6448-6453.
12. Frost, D., Gorman, P.M., Yip, C.M., and Chakrabartty, A. (2003) Co-incorporation of A beta 40 and A beta 42 to form mixed pre-fibrillar aggregates. Eur. J. Biochem., 270, 654-663.
13. Lorenzo, A. and Yankner, B.A. (1994) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo Red. Proc. Natl. Acad. Sci. USA, 91, 12243-12247.
14. Podlisny, M.B., Ostaszewski, B.L., Squazzo, S.L., Koo, E.H., Rydell, R.E., Teplow, D.B., and Selkoe, D.J. (1995) Aggregation of secreted amyloid betaprotein into sodium dodecyl sulfate-stable oligomers in cell culture. J. Biol. Chem., 270, 9564-9570.
15. Podlisny, M.B., Walsh, D.M., Amarante, P., Ostaszewski, B.L., Stimson, E.R., Maggio, J.E., Teplow, D.B., and Selkoe, D.J. (1998) Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo Red. Biochemistry, 37, 3602-3611.
16. Walsh, D.M., Hartley, D.M., Kusumoto, Y., Fezoui, Y., Condron, M.M., Lomakin, A., Benedek, G.B., Selkoe, D.J., and Teplow, D.B. (1999) Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem., 274, 25945-25952.
17. Dahlgren, K.N., Manelli, A.M., Stine, W.B.J., Baker, L.K., Krafft, G.A., and LaDu, M.J. (2002) Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem., 277, 32046-32053.
18. Stine, W.B.J., Dahlgren, K.N., Krafft, G.A., and LaDu, M.J. (2003) In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J. Biol. Chem., 278, 11612-11622.
19. Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J., and Selkoe, D.J. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature, 416, 535-539.
20. Walsh, D.M., Tseng, B.P., Rydel, R.E., Podlisny, M.B., and Selkoe, D.J. (2000) The oligomerization of amyloid betaprotein begins intracellularly in cells derived from human brain. Biochemistry, 39, 10831-10839.
21. Bateman, D.A. and Chakrabartty, A. (2004) Interactions of Alzheimer amyloid peptides with cultured cells and brain tissue, and their biological consequences. Biopolymers, 76, 4-14.
22. Bateman, D.A. and Chakrabartty, A. (2009) Two distinct conformations of Abeta aggregates on the surface of living PC12 cells. Biophys. J., 96, 4260-4267.
23. Bateman, D.A., McLaurin, J., and Chakrabartty, A. (2007) Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface binding. BMC Neurosci., 8, 29.
24. Luo, Y., Hawver, D.B., Iwasaki, K., Sunderland, T., Roth, G.S., and Wolozin, B. (1997) Physiological levels of beta-amyloid peptide stimulate protein kinase C in PC12 cells. Brain Res., 769, 287-295.
25. Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schlossmacher, M., Whaley, J., Swindlehurst, C. et al. (1992) Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature, 359, 325-327.
26. Hardy, J.A. and Higgins, G.A. (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science, 256, 184-185.
27. Wood, S.J., Maleeff, B., Hart, T., and Wetzel, R. (1996) Physical, morphological and functional differences between pH 5.8 and 7.4 aggregates of the Alzheimer's amyloid peptide Abeta. J. Mol. Biol., 256, 870-877.
28. Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W., and Glabe, C.G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science, 300, 486-489.
29. Lambert, M.P., Viola, K.L., Chromy, B.A., Chang, L., Morgan, T.E., Yu, J., Venton, D.L., Krafft, G.A., Finch, C.E., and Klein, W.L. (2001) Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J. Neurochem., 79, 595-605.
30. Kheterpal, I., Williams, A., Murphy, C., Bledsoe, B., and Wetzel, R. (2001) Structural features of the Abeta amyloid fibril elucidated by limited proteolysis. Biochemistry, 40, 11757-11767.
31. Petkova, A.T., Yau, W., and Tycko, R. (2006) Experimental constraints on quaternary structure in Alzheimer's beta-amyloid fibrils. Biochemistry, 45, 498-512.
32. Huang, T.H., Yang, D.S., Plaskos, N.P., Go, S., Yip, C.M., Fraser, P.E., and Chakrabartty, A. (2000) Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide. J. Mol. Biol., 297, 73-87.
33. Huang, T.H., Fraser, P.E., and Chakrabartty, A. (1997) Fibrillogenesis of Alzheimer Abeta peptides studied by fluorescence energy transfer. J. Mol. Biol., 269, 214-224.
34. Sengupta, P., Garai, K., Sahoo, B., Shi, Y., Callaway, D.J.E., and Maiti, S. (2003) The amyloid beta peptide (Abeta(1-40)) is thermodynamically soluble at physiological concentrations. Biochemistry, 42, 10506-10513.
35. Tjernberg, L.O., Pramanik, A., Björling, S., Thyberg, P., Thyberg, J., Nordstedt, C., Berndt, K.D., Terenius, L., and Rigler, R. (1999) Amyloid beta-peptide polymerization studied using fluorescence correlation spectroscopy. Chem. Biol., 6, 53-62.
36. Hazum, E., Cuatrecasas, P., Marian, J., and Conn, P.M. (1980) Receptor-mediated internalization of fluorescent gonadotropin-releasing hormone by pituitary gonadotropes. Proc. Natl. Acad. Sci. USA, 77, 6692-6695.
37. Smith, M.L., Carski, T.R., and Griffin, C.W. (1962) Modification of fluorescent-antibody procedures employing crystalline tetramethylrhodamine isothiocyanate. J. Bacteriol., 83, 1358-1359.
38. Young, R.M., Arnette, J.K., Roess, D.A., and Barisas, B.G. (1994) Quantitation of fluorescence energy transfer between cell surface proteins via fluorescence donor photobleaching kinetics. Biophys. J., 67, 881-888.
39. Slavik, J. (1994) Fluorescent Probes in Cellular and Molecular Biology, CRC Press, Boca Raton, FL, pp. 241-279.
40. Baneyx, G. and Vogel, V. (1999) Selfassembly of fibronectin into fibrillar networks underneath dipalmitoyl phosphatidylcholine monolayers: role of lipid matrix and tensile forces. Proc. Natl. Acad. Sci. USA, 96, 12518-12523.
41. Umberger, J.Q. and LaMer, V.K. (1945) The kinetics of diffusion controlled molecular and ionic reactions in solution as determined by measurements of the quenching of fluorescence. J. Am. Chem. Soc., 67, 1099-1109.
42. Michikawa, M., Gong, J.S., Fan, Q.W., Sawamura, N., and Yanagisawa, K. (2001) A novel action of Alzheimer's amyloid beta-protein (Abeta): oligomeric Abeta promotes lipid release. J. Neurosci., 21, 7226-7235.
43. Mendez, A.J., Oram, J.F., and Bierman, E.L. (1991) Protein kinase C as a mediator of high density lipoprotein receptor-dependent efflux of intracellular cholesterol. J. Biol. Chem., 266, 10104-10111.
44. Gong, J., Sawamura, N., Zou, K., Sakai, J., Yanagisawa, K., and Michikawa, M. (2002) Amyloid beta-protein affects cholesterol metabolism in cultured neurons: implications for pivotal role of cholesterol in the amyloid cascade. J. Neurosci. Res., 70, 438-446.
45. Waschuk, S.A., Elton, E.A., Darabie, A.A., Fraser, P.E., and McLaurin, J.A. (2001) Cellular membrane composition defines Abeta-lipid interactions. J. Biol. Chem., 276, 33561-33568.
46. McLaurin, J., Franklin, T., Fraser, P.E., and Chakrabartty, A. (1998) Structural transitions associated with the interaction of Alzheimer beta-amyloid peptides with gangliosides. J. Biol. Chem., 273, 4506-4515.
47. McLaurin, J. and Chakrabartty, A. (1996) Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity. J. Biol. Chem., 271, 26482-26489.
48. Yanagisawa, K. and Ihara, Y. (1998) GM1 ganglioside-bound amyloid beta-protein in Alzheimer's disease brain. Neurobiol. Aging, 19, S65-S67.
49. Yanagisawa, K., Odaka, A., Suzuki, N., and Ihara, Y. (1995) GM1 ganglioside-bound amyloid beta-protein (Abeta): a possible form of preamyloid in Alzheimer's disease. Nat. Med., 1, 1062-1066.
50. Lee, G., Pollard, H.B., and Arispe, N. (2002) Annexin 5 and apolipoprotein E2 protect against Alzheimer's amyloid-betapeptide cytotoxicity by competitive inhibition at a common phosphatidylserine interaction site. Peptides, 23, 1249-1263.
51. Simakova, O. and Arispe, N.J. (2007) The cell-selective neurotoxicity of the Alzheimer's Abeta peptide is determined by surface phosphatidylserine and cytosolicATP levels.Membrane binding is required for Abeta toxicity. J. Neurosci., 27, 13719-13729.
52. Klunk, W.E., Bacskai, B.J., Mathis, C.A., Kajdasz, S.T., McLellan, M.E., Frosch, M.P., Debnath, M.L., Holt, D.P., Wang, Y., and Hyman, B.T. (2002) Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo Red derivative. J. Neuropathol. Exp. Neurol., 61, 797-805.
53. Kung, M., Hou, C., Zhuang, Z., Zhang, B., Skovronsky, D., Trojanowski, J.Q., Lee, V.M., and Kung, H.F. (2002) IMPY: an improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques. Brain Res., 956, 202-210.
54. Maggio, J.E., Stimson, E.R., Ghilardi, J.R., Allen, C.J., Dahl, C.E., Whitcomb, D.C., Vigna, S.R., Vinters, H.V., Labenski, M.E., and Mantyh, P.W. (1992) Reversible in vitro growth of Alzheimer disease betaamyloid plaques by deposition of labeled amyloid peptide. Proc. Natl. Acad. Sci. USA, 89, 5462-5466.
55. Burdick, D., Kosmoski, J., Knauer, M.F., and Glabe, C.G. (1997) Preferential adsorption, internalization and resistance to degradation of the major isoform of the Alzheimer's amyloid peptide, Abeta 1-42, in differentiated PC12 cells. Brain Res., 746, 275-284.
56. Lambert, M.P., Viola, K.L., Chromy, B.A., Chang, L., Morgan, T.E., Yu, J., Venton, D.L., Krafft, G.A., Finch, C.E., and Klein, W.L. (2001) Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J. Neurochem., 79, 595-605.
57. Lacor, P.N., Buniel, M.C., Chang, L., Fernandez, S.J., Gong, Y., Viola, K.L., Lambert, M.P., Velasco, P.T., Bigio, E.H., Finch, C.E., Krafft, G.A., and Klein, W.L. (2004) Synaptic targeting by Alzheimer'srelated amyloid beta oligomers. J. Neurosci., 24, 10191-10200.
58. Kokubo, H., Kayed, R., Glabe, C.G., and Yamaguchi, H. (2005) Soluble Abeta oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain. Brain Res., 1031, 222-228.
59. Lee, E.B., Leng, L.Z., Zhang, B., Kwong, L., Trojanowski, J.Q., Abel, T., and Lee, V.M. (2006) Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J. Biol. Chem., 281, 4292-4299.